🇺🇸 DPP4 inhibitor in United States

18 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Ineffective — 3 reports (16.67%)
  2. Nausea — 3 reports (16.67%)
  3. Vomiting — 3 reports (16.67%)
  4. Abdominal Pain — 2 reports (11.11%)
  5. Weight Decreased — 2 reports (11.11%)
  6. Acute Kidney Injury — 1 report (5.56%)
  7. Adult T-Cell Lymphoma/Leukaemia — 1 report (5.56%)
  8. Anuria — 1 report (5.56%)
  9. Blood Glucose Decreased — 1 report (5.56%)
  10. Blood Sodium Decreased — 1 report (5.56%)

Source database →

DPP4 inhibitor in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Diabetes approved in United States

Frequently asked questions

Is DPP4 inhibitor approved in United States?

DPP4 inhibitor does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for DPP4 inhibitor in United States?

AstraZeneca is the originator. The local marketing authorisation holder may differ — check the official source linked above.